Gan & Lee Pharmaceuticals.
603087
Pozycja w akcjach
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Cena akcji
$10.03
Kapitalizacja rynkowa
$5.99B
Zmiana (1 dzień)
-3.71%
Zmiana (1 rok)
2.30%
Kraj
CN
Handel Gan & Lee Pharmaceuticals. (603087)
Kategoria
Healthcare
Zyski dla Gan & Lee Pharmaceuticals. (603087)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Gan & Lee Pharmaceuticals., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Gan & Lee Pharmaceuticals. od 2013 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2025 | $175.78M | 103.53% |
| 2024 | $86.36M | 99.69% |
| 2023 | $43.25M | -151.22% |
| 2022 | $-84.44M | -131.65% |
| 2021 | $266.84M | 20.60% |
| 2020 | $221.27M | 10.25% |
| 2019 | $200.69M | 23.97% |
| 2018 | $161.88M | -16.93% |
| 2017 | $194.88M | 49.21% |
| 2016 | $130.61M | 61.32% |
| 2015 | $80.96M | 41.18% |
| 2014 | $57.35M | 44.07% |
| 2013 | $39.81M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $3.62B | - |
US
|
|
| $4.11B | - |
FR
|
|
| - | - |
JP
|
|
| $1.59B | - |
US
|
|
| - | - |
CH
|
